Rheumatology

Northwell Opens $52M Cancer Center, Multispecialty Practice in Queens

Retrieved on: 
Tuesday, November 28, 2023
General Health, Hospitals, Health, Practice Management, Oncology, Queens Boulevard, Hindi, Oncology nursing, North Shore University Hospital, Gynaecology, Cancer Institute, LIJ, New Yorker, Head, Cardiology, Endocrinology, Genetic counseling, Surgical oncology, Hematology, Elective surgery, DEXA, Internal medicine, Urology, Breast cancer, Google Images, Patient, Multimedia, Gastrointestinal cancer, Colorectal surgery, Kimelman Cancer Institute, Neurology, Heart, Obstetrics, Rheumatology, MD Anderson Cancer Center, Rehabilitation, Bariatrics, Lung cancer screening, Gastroenterology, HIV, Neurosurgery, Cancer, QMA, MRI, Social work, Hospital, PET, General surgery, STARS, Estate (law), Nursing, Management, MD, Northwell Health

As part of the new cancer center, Queens Medical Associates (QMA), a member of the Northwell Health Cancer Institute, will move its highly regarded hematology and oncology practice, located in Fresh Meadows for over 30 years, to Rego Park.

Key Points: 
  • As part of the new cancer center, Queens Medical Associates (QMA), a member of the Northwell Health Cancer Institute, will move its highly regarded hematology and oncology practice, located in Fresh Meadows for over 30 years, to Rego Park.
  • Northwell treats about 19,000 New Yorkers with cancer each year, more than any other cancer provider in the state.
  • “We’re excited to open a new outpatient cancer center in the heart of Queens to deliver the best cancer care close to where people live,” said Richard Barakat, MD , physician-in-chief and executive director of the Northwell Health Cancer Institute.
  • “Northwell is uniquely positioned to care for patients in Queens – one of the most diverse places in the country.

ROME Therapeutics Presents First Data to Validate LINE-1 RT as a Novel Target in Autoimmune Diseases and the Therapeutic Potential of its First-in-Class LINE-1 RT Inhibitors

Retrieved on: 
Thursday, November 16, 2023
Health, Biotechnology, DNA, Therapy, Pathology, University, Cytoplasm, Keratinocyte, Patient, UV, Autoantibody, American College of Rheumatology, Autoimmune disease, Heart, Kidney, American College, SLE, DSM-IV codes, Drug discovery, RT, RNA, AGS, Skin, ACR, Quality of life, Lupus, Poster, Biology, Inflammation, Pharmaceutical industry, Vaccine, Rheumatology

Data also demonstrated the therapeutic potential of the company’s first-in-class LINE-1 RT inhibitors to stop disease-driving inflammation.

Key Points: 
  • Data also demonstrated the therapeutic potential of the company’s first-in-class LINE-1 RT inhibitors to stop disease-driving inflammation.
  • Additionally, the poster highlighted the first preclinical data demonstrating the therapeutic potential of ROME’s first-in-class inhibitors of LINE-1 RT.
  • These data are the first to validate LINE-1 RT as a novel target for potential therapeutic intervention across a wide range of autoimmune diseases,” said Rosana Kapeller, M.D., Ph.D., President, CEO and Co-founder of ROME.
  • “We’re also pleased to share the first in vivo and in vitro data validating the therapeutic effect of our first-in-class LINE-1 RT inhibitors in the autoimmune disease setting.

Alpine Immune Sciences Presents New Translational Data on Povetacicept in Systemic Lupus Erythematosus at American College of Rheumatology Convergence 2023

Retrieved on: 
Wednesday, November 15, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, APRIL, Rheumatology, WT, Patient, TACI, Inflammation, Lupus, American College, Glomerulonephritis, BAFF, SLE, ALPN, Immunoglobulin A, Trial of the century, BCMA, Autoimmunity, IgA nephropathy, Pharmaceutical industry, Vaccine

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, announced today that the Company presented new translational data for povetacicept (ALPN-303) in systemic lupus erythematosus (SLE) at the American College of Rheumatology Convergence 2023, November 10-15, 2023.

Key Points: 
  • Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, announced today that the Company presented new translational data for povetacicept (ALPN-303) in systemic lupus erythematosus (SLE) at the American College of Rheumatology Convergence 2023, November 10-15, 2023.
  • In SLE patients, BAFF- and APRIL-related genes (i.e., BAFF, APRIL, TACI, and BCMA) are increased in myeloid lineage cells and B cells compared to healthy adults.
  • Povetacicept, as compared to single BAFF or APRIL pathway inhibitors, more potently downregulates genes associated with activation in B cells.
  • Povetacicept significantly reduces multiple disease parameters in a mouse model of lupus, more effectively than WT TACI-Fc or conventional B cell depletion.

KalVista Pharmaceuticals Presents Real-World Data at the 2023 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology

Retrieved on: 
Tuesday, November 14, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Syringe, Real, Attack, Asthma, Lung compliance, Patient, Division, American College, Internal medicine, Hereditary angioedema, Anxiety, KALV, HAE, University, Pain, University of California, Freie Berliner Kunstausstellung, ACAAI, Rheumatology, Immunology

“We continue to learn from people living with HAE that currently available parenteral on-demand treatments are simply not meeting their needs,” said Andrew Crockett, Chief Executive Officer of KalVista.

Key Points: 
  • “We continue to learn from people living with HAE that currently available parenteral on-demand treatments are simply not meeting their needs,” said Andrew Crockett, Chief Executive Officer of KalVista.
  • “Whether this is related to always carrying their syringes or vials, challenges in preparing and administering injectable or infused treatments outside the home, or anxiety related to potential injection-site reactions and pain, patients struggle to follow treatment guidelines.
  • This can lead to non-compliance and preference for long-term prophylaxis, even in cases where on-demand treatments would otherwise suffice.
  • We also note that despite the use of long-term prophylaxis, HAE patients require HAE-related home health visits and seek ER treatment more often than would be expected.

Northwell Health Pediatric Rheumatologist Recognized for Lifetime Achievement by the American College of Rheumatology

Retrieved on: 
Tuesday, November 14, 2023
Children, Biotechnology, Other Consumer, Other Health, Health, General Health, Other Science, Research, Consumer, Science, Teens, Interest group, CCMC, Hope, Pediatrics, Patient, Multimedia, Lupus, American College of Rheumatology, Arthritis, American College, Northwell Health, Rheumatology, Medical research, Dermatomyositis, Mentorship, Credit, MBA, MD, Eberhard, ACR, ARP, Vasculitis, Nursing, Child

For her dedication to research and leadership in rheumatology, Northwell Health’s Cohen Children’s Medical Center (CCMC) pediatric rheumatologist and Feinstein Institutes for Medical Research scientist Barbara Anne Eberhard, MD , has been awarded top honors by the American College of Rheumatology (ACR) and the Association of Rheumatology Professionals (ARP).

Key Points: 
  • For her dedication to research and leadership in rheumatology, Northwell Health’s Cohen Children’s Medical Center (CCMC) pediatric rheumatologist and Feinstein Institutes for Medical Research scientist Barbara Anne Eberhard, MD , has been awarded top honors by the American College of Rheumatology (ACR) and the Association of Rheumatology Professionals (ARP).
  • Dr. Eberhard was recognized, and named an “ACR Master,” during the ACR Convergence 2023 annual conference which is being held November 10-15 in San Diego, California.
  • View the full release here: https://www.businesswire.com/news/home/20231114668794/en/
    Dr. Barbara Anne Eberhard was recognized for lifetime achievement by the American College of Rheumatology.
  • (Credit: Feinstein Institutes)
    The ACR Master recognition is awarded to physician-researchers who have made significant contributions to the field of rheumatology.

NImmune Biopharma Presents Positive First-in-Human Data of NIM-1324, a Phase 2 Candidate for Systemic Lupus Erythematosus at the American College of Rheumatology Convergence 2023 (#ACR23)

Retrieved on: 
Tuesday, November 14, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, San Diego Convention Center, Safety, Randomness, Treatment, LANCL2, Plasma, Hematology, A.I, Rheumatoid arthritis, Urinalysis, American College, SLE, Therapy, IBD, Volunteering, Abstract, Biochemistry, Arthritis, Gastrointestinal tract, Rheumatology, Lupus, ACR, Poster, Pharmaceutical industry, Copper, Ulcerative colitis

“Systemic lupus erythematosus (SLE) has a very high unmet medical need.

Key Points: 
  • “Systemic lupus erythematosus (SLE) has a very high unmet medical need.
  • First in human results of our wholly-owned NIM-1324 in SLE met all primary and secondary endpoints of safety and tolerability.
  • The poster will be available under the “Publications” section of NIMML’s website at www.nimml.org and at the ACR Convergence 2023 virtual poster gallery.
  • Additionally, the peer-reviewed accepted abstracts will be published in a special online supplement of the Arthritis & Rheumatology Journal.

Kezar Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Monday, November 13, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Downregulation and upregulation, ISCB Senior Scientist Award, Annual general meeting, Safety, ALT, Cohort, UPCR, AIH, Immunosuppression, Clinical trial, Patient, KZR, OLE, Week, American College of Rheumatology, Immunotherapy, Mount Everest, G&A, Pharmacokinetics, Polymyositis, American College, PD-1, University, Dermatomyositis, Lupus nephritis, SITC, Total, Autoimmune hepatitis, Growth, CRR, Congress, ACR, APLAR, Society, Sec61, Pharmaceutical industry, Rheumatology, Kezar Pavilion

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing breakthrough treatments for immune-mediated and oncologic disorders, today reported financial results for the third quarter ended September 30, 2023 and provided a business update.

Key Points: 
  • Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing breakthrough treatments for immune-mediated and oncologic disorders, today reported financial results for the third quarter ended September 30, 2023 and provided a business update.
  • In addition, Kezar recently announced a strategic restructuring to prioritize long-term growth and focus resources on its clinical-stage programs.
  • Actions to prioritize clinical programs and implement cost saving measures are expected to extend Kezar’s cash runway into late 2026.
  • Research and development expenses for the third quarter of 2023 increased by $9.8 million to $23.7 million compared to $13.9 million in the third quarter of 2022.

Alpine Immune Sciences Presents New Translational Data on Acazicolcept in Systemic Lupus Erythematosus at American College of Rheumatology Convergence 2023

Retrieved on: 
Monday, November 13, 2023
Biotechnology, Genetics, Health, Clinical Trials, Gene, Rheumatology, Patient, Inflammation, Synergy, Lupus, American College, CD28, SLE, ALPN, CD80, Alpine, ICOS, Autoimmunity, Immunoglobulin G, CD86, Pharmaceutical industry, Vaccine, Research

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, announced today that the Company presented new translational data for acazicolcept (ALPN-101) in systemic lupus erythematosus (SLE) at the American College of Rheumatology Convergence 2023, November 10-15, 2023.

Key Points: 
  • Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, announced today that the Company presented new translational data for acazicolcept (ALPN-101) in systemic lupus erythematosus (SLE) at the American College of Rheumatology Convergence 2023, November 10-15, 2023.
  • Acazicolcept target-related genes (ICOS, CD80, CD86) are upregulated in the T and B cells of SLE patients compared to healthy adults.
  • Acazicolcept reduces pathogenic hypergammaglobulinemia and glomerular IgG deposition in a mouse model of lupus.
  • Clinical investigation of acazicolcept for the treatment of SLE, such as in our ongoing phase 2 study, Synergy, continues to be supported.”

medac cooperates with Scienta Lab to generate new insights in rheumatology care with AI-powered solutions

Retrieved on: 
Tuesday, December 12, 2023
Research, Ekipa, Patient, Artificial intelligence, Rheumatology, Partnership, AI, Medac, Medical device

WEDEL, Germany, Dec. 12, 2023 /PRNewswire/ -- medac is breaking new ground and cooperating with Scienta Lab, an innovative AI company based in France.

Key Points: 
  • WEDEL, Germany, Dec. 12, 2023 /PRNewswire/ -- medac is breaking new ground and cooperating with Scienta Lab, an innovative AI company based in France.
  • medac has already underlined its commitment to new ideas and digital solutions by initiating the Ekipa Challenge "Innovate Rheumatology".
  • As part of this challenge, the company deepened the contact with Scienta Lab, a French company with expertise in AI and immunology.
  • This partnership demonstrates the commitment of medac to support a personalized therapy journey in rheumatology thanks to innovative solutions.

medac cooperates with Scienta Lab to generate new insights in rheumatology care with AI-powered solutions

Retrieved on: 
Tuesday, December 12, 2023
Research, Ekipa, Patient, Artificial intelligence, Rheumatology, Partnership, AI, Medac, Medical device

WEDEL, Germany, Dec. 12, 2023 /PRNewswire/ -- medac is breaking new ground and cooperating with Scienta Lab, an innovative AI company based in France.

Key Points: 
  • WEDEL, Germany, Dec. 12, 2023 /PRNewswire/ -- medac is breaking new ground and cooperating with Scienta Lab, an innovative AI company based in France.
  • medac has already underlined its commitment to new ideas and digital solutions by initiating the Ekipa Challenge "Innovate Rheumatology".
  • As part of this challenge, the company deepened the contact with Scienta Lab, a French company with expertise in AI and immunology.
  • This partnership demonstrates the commitment of medac to support a personalized therapy journey in rheumatology thanks to innovative solutions.